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Abstract In the present study we assessed the contribution of
acidic sphingomyelinase (ASMase), a ceramide generating en-
zyme, in tumor necrosis factor (TNF)-mediated apoptosis in
human colon HT-29 cells. TNF induced apoptosis in HT-29
cells in a time- and dose-dependent fashion. Downregulation
of the active endogenous ASMase form prevented TNF-stimu-
lated ASMase activity and apoptosis. Furthermore, inhibition of
glucosylceramide synthase, which blunted TNF-stimulated GD3
levels, abolished TNF-mediated cell death. Immunocytochemical
staining revealed the co-localization of GD3 with mitochondria
induced by TNF. The knockdown of targeted GD3 synthase by
antisense expression vector protected HT-29 cells against TNF-
induced cell death. Thus, ASMase plays a key role in TNF-
induced cell death in human colon epithelial cells possibly
through GD3 generation. + 2002 Published by Elsevier Sci-
ence B.V. on behalf of the Federation of European Biochemical
Societies.
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1. Introduction
Tumor necrosis factor (TNF) is a pleiotropic cytokine that
induces a wide variety of cellular responses including apopto-
sis. The mechanisms involved in TNF-induced apoptosis are
complex and involve protein^protein interactions and gener-
ation of signaling intermediates [1^4].
The TNF binding to its plasma membrane receptor-1 has
been reported to generate ceramide, a sphingolipid that has
been implicated in apoptosis [5,6]. Ceramide levels can in-
crease through several mechanisms, including the de novo
synthesis from L-serine and palmitoyl-CoA catalyzed by the
action of serine-palmitoyl transferase and the activation of
ceramide synthase [7^9]. Indeed, the latter has been reported
to mediate TNF-mediated cell death in MCF7 cells [10]. On
the other hand, ceramide levels can increase by hydrolysis of
membrane sphingomyelin by the action of sphingomyelinases
(SMases). Several SMases have been identi¢ed, although not
all of them have been fully characterized. The magnesium-
dependent, membrane-bound, neutral SMase (NSMase) has
been linked to apoptosis mediated by chemotherapeutic
agents, serum starvation, TNF, and Fas [10^12]. Acidic
SMase (ASMase), which displays an optimum pH around
4.8, has been further subclassi¢ed into the endosomal/lyso-
somal ASMase and a secretory Zn2þ-dependent SMase [5^
7,13^15]. Although ASMase has been shown to mediate de-
velopmental apoptosis and ionizing radiation-mediated cell
death [16,17], its role in death-ligand-induced apoptosis is
controversial. Decreased ceramide production by ASMase
due to overexpression of acid ceramidase has been shown to
protect L929 cells from TNF-induced cell death [18] ; how-
ever, inhibition of ASMase early but not late during TNF
signaling protected ML-1a cells against TNF [19]. Finally,
hepatocytes de¢cient in ASMase showed resistance to Fas-
mediated apoptosis [20,21], but studies using lymphocytes de-
rived from Niemann^Pick patients with minimal ASMase
have yielded con£icting results in Fas-mediated cell death
[22,23].
In addition to its involvement in apoptosis signaling, cer-
amide also functions as a precursor for the synthesis of gly-
cosphingolipids (GSLs). GSLs participate in the regulation of
various cellular functions, including cell adhesion and modu-
lators of signal transduction [24,25]. In particular, GD3, a
sialic acid-containing GSL, has been identi¢ed as a lipid death
e¡ector due to its ability to interact and recruit mitochondria
to apoptotic pathways, contributing to the mitochondrial-de-
pendent apoptosome activation triggered by death ligands
[26^31]. Increased GD3 levels have been reported to mediate
Fas-mediated cell death in lymphoid cells [31,32].
Despite the emerging function of GSLs, e.g. GD3, in apo-
ptosis, their role in TNF-mediated cell death in human colon
epithelial cells has not been examined. Thus, the purpose of
our work was to assess the role of ASMase in TNF-mediated
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apoptosis in HT-29 cells and to estimate the relative contri-
bution of GSLs in this function. In this paper, we provide
evidence that the ceramide pool contributing to TNF-induced
apoptosis derives from ASMase and this role is accomplished
through GSLs formation, possibly through the speci¢c gener-
ation of ganglioside GD3.
2. Materials and methods
2.1. Cell culture and experimental conditions
The human colon cancer cell line, HT-29, was purchased from the
European Collection of Animal Cell Cultures (Salisbury, Wilts, UK).
HT-29 cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
containing 25 mM glucose in the presence of 100 U/ml penicillin,
100 Wg/ml streptomycin and 10% heat-inactivated fetal bovine serum.
Cells (5U105 cells/ml) were seeded into six-well plates and con£uent
cell monolayers were then incubated for various periods of time with
human recombinant TNF (14^280 ng/ml, Promega, Barcelona,
Spain). In some cases, cells were pretreated with imipramine or
N-butyldeoxynojirimycin (NB-DNJ) before exposure to TNF. Under
the experimental conditions (TNF treatment in the absence or pres-
ence of imipramine or NB-DNJ) HT-29 cells did not undergo enter-
ocytic-like di¡erentiation as veri¢ed by the absence of stimulated re-
lease of carcinoembryogenic antigen (CEA) into the medium as
described before [33].
2.2. Determination of cell death and apoptosis
Cell survival was quantitated by the MTT assay by adding MTT
(20 Wl of 5 mg/ml MTT in phosphate-bu¡ered saline (PBS)) and
monitoring the absorbance at 570 nm. This approach was validated
by the release of LDH into the medium, expressed as percentage of
total LDH (cells plus medium). Apoptotic features of cell death were
determined by the staining of cells with the DNA-binding £uoro-
chrome H33258 assessing chromatin condensation by £uorescence
microscope analyses or nuclear DNA fragmentation by gel electro-
phoresis.
2.3. ASMase downregulation
Endogenous ASMase was depleted before treatment with TNF by
incubation of HT-29 cells with imipramine (20 WM), which stimulates
the proteolytic degradation of ASMase [34]. HT-29 cells were washed
twice in PBS and resuspended in 1 ml of bu¡er (10 mM HEPES, pH
7.8, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithiothrei-
tol and 1 mM phenylsulfonyl £uoride). After incubation for 15 min
on ice, cells were homogenized using a Potter^Elvehjem homogenizer.
Nuclei and cell debris were removed by low speed centrifugation
(800Ug). Supernatants containing cytosolic and membrane proteins
(50^60 Wg) were resolved by SDS^PAGE and proteins were trans-
ferred to nitrocellulose membranes. Blots were incubated with goat
anti-ASMase polyclonal IgG (1:2500), provided by Dr. Sandho¡
(Universita«t Bonn), and goat anti-IgG antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) (1:5000) followed by ECL-based de-
tection (Amersham, Madrid, Spain). ASMase activity in cellular ex-
tracts was determined by monitoring [N-methyl-14C]sphingomyelin
(56.6 mCi/mmol) hydrolysis as described before [35].
2.4. Sphingolipids analyses
Cellular lipids after treatment were extracted in chloroform:metha-
nol (1:1, v/v). Ceramide levels were determined by the diacylglycerol
kinase assay in thin layer chromatography (TLC) plates developed in
chloroform:acetic (9:1, v/v) or high performance liquid chromatogra-
phy (HPLC) after derivatization of the sphingoid base with O-phthal-
dehyde following deacylation of ceramide as characterized previously
[35]. The aqueous phase containing glycolipids was loaded in a Sep-
Pak C18 cartridge and applied to high performance thin layer chro-
matography (HPTLC) plates, resolved and developed as described
previously [28]. The levels of GSLs were calculated by densitometric
analyses of HPTLC plates, compared with a standard curve generated
using known amounts of glucosylceramide (GluCer), lactosylceramide
(LactCer), GM1, GM3 and GD3 (Matreya, Pleasant Gap, PA, USA,
99% purity by TLC). The variability between individual experiments
was below 18%. Alternatively, GD3 was detected and quantitated by
immunostaining in aluminum-baked silica gel 60 HPTLC plates fol-
lowed by incubation with 0.5% poly-isobutylmetacrylate in hexane
and exposure to mouse anti-GD3 R24 antibody (Matreya, Pleasant
Gap, PA, USA) [31]. Plates were then treated with horseradish per-
oxidase-conjugated goat anti-mouse IgG, and GD3 was visualized by
immunoperoxidase staining.
2.5. Confocal microscopy
Cellular distribution of GD3 was accomplished by immunocyto-
chemical staining using the mouse anti-GD3 R24 antibody (1:500)
as described before [31]. The co-localization of GD3 with respect to
mitochondria was assessed using human anti-mitochondrial serum
(1:2000) obtained from the serum of a patient with primary biliary
cirrhosis, shown to recognize the E2 epitope of the mammalian mi-
tochondrial pyruvate dehydrogenase complex [36]. Brie£y, cells were
¢xed for 10 min in 3.7% paraformaldehyde in 0.1 M phosphate bu¡er
prior to permeabilization with 0.1% saponin in 0.5% bovine serum
albumin/PBS bu¡er for 15 min. The anti-mitochondrial antibody was
detected using a biotin-SP-conjugated mouse anti-human IgG fol-
lowed by a streptavidin^FITC conjugate (BioSource International,
Leeds, UK), whereas the anti-mouse IgG-Cy3-conjugated antibody
(Jackson ImmunoResearch, West Grove, PA, USA) was used to de-
tect the mouse anti-GD3 R24 antibody. After ¢nal washes in PBS,
cells were mounted in Mowiol. Confocal images were collected using a
Leica TCS-NT laser scanning confocal microscope equipped with an
argon^krypton laser and a 63U Leitz Plan-Apo objective (NA 1.4).
More than 200 cells per condition at di¡erent ¢elds were examined for
GD3 and mitochondrial co-localization.
2.6. Stable transfection of HT-29 cells
Stably transfected HT-29 cells were generated using the mammalian
expression vector pCR3.1 (Invitrogen) containing the antisense GD3
synthase cDNA, a gift of Drs. Yu and Zeng (Medical College of
Georgia) described previously [37], in the presence of Lipofect-
amine2000 (Invitrogen). Isolation of single clones was accomplished
by selection adding geneticin (Invitrogen) to the culture medium at
500 Wg/ml. After 3 weeks, 15^20 geneticin-resistant clones were pooled
and expanded. Plasmid integration was tested by PCR using total
DNA isolated with DNAzol reagent (Invitrogen) from transfected
cells. cDNA inserts were visualized by PCR using speci¢c primers
for the pCR3.1 vector (5P-GGGAAGAGCCTGTGGTATGA-3P)
and GD3 synthase cDNA (5P-CACCTTCCAGGGTCAAGGAA-3P,
GenBank1 accession number U53883). PCR products were analyzed
by 1% agarose gel electrophoresis and stained with ethidium bromide.
GD3 synthase activity was determined using CMP-[3H]-N-acetylneur-
aminic acid (New England Nuclear, Boston, MA, USA, 19.7 mCi/
mmol) as described before in detail [37]. Glycolipid products were
separated by Sephadex G50 gel ¢ltration and their radioactivities
measured by liquid scintillation counting.
2.7. Statistical analyses
Results are expressed as the meanUS.D. and are averages of three
to ¢ve values per experiment. Statistical analyses of mean values for
multiple comparisons were made by one-way analysis of variance.
3. Results and discussion
3.1. Downregulation of ASMase protects HT-29 cells against
TNF-mediated apoptosis
In order to assess the speci¢c role of ASMase, a ceramide
generating enzyme of relevance in TNF signaling [5,6], in
TNF-induced cell death in HT-29 cells, we ¢rst characterized
their susceptibility to TNF exposure. As shown, TNF induced
a dose-dependent loss of viability that increased over time
(Fig. 1A). At the lower dose of TNF tested (14 ng/ml) apo-
ptosis became signi¢cant after more than 20 h of incubation
(Fig. 1A). To con¢rm the incidence of apoptosis, we moni-
tored chromatin morphology by £uorescence microscopy. As
seen, TNF disrupted chromating integrity, an indication of
apoptotic cell death (Fig. 1B). The magnitude of ceramide
generation by TNF was dependent on the dose used
(264U 21% and 442U 48% at 14 ng/ml and 280 ng/ml, respec-
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tively). This increase occurred between 1 and 2 h post-incu-
bation, preceding the onset of cell death by TNF. Further-
more, TNF activated both NSMase and ASMase within 20
min after TNF exposure (not shown).
The next step was to evaluate the role of ASMase in TNF-
mediated apoptosis. To this end endogenous ASMase was
downregulated prior to TNF exposure. Imipramine, a tricyclic
anti-depressant, has been described to induce the proteolytic
degradation of the active ASMase form [34]. Although TNF
increased the level of the active ASMase, HT-29 cells pre-
treated with imipramine exhibited lowered levels of ASMase,
as revealed by Western blot (Fig. 2A). This e¡ect of imip-
ramine which was accompanied by decreased basal activity
suppressed the stimulation of ASMase induced by TNF
(Fig. 2B). Imipramine treatment, however, did not a¡ect the
TNF-stimulated activity of NSMase (Fig. 2C). Despite that
imipramine preincubation prevented the stimulation of AS-
Mase by TNF, this approach did not abolish the increase of
ceramide induced by TNF (Fig. 2D). Finally, the role of
imipramine preincubation was examined on the survival of
HT-29 following TNF treatment. As shown, imipramine pre-
treatment abolished TNF-induced loss of cell viability (Fig.
2E). Under the present conditions, TNF, however, did not
induce di¡erentiation of HT-29 as veri¢ed by the lack of
CEA release, ¢ndings that are in line with previous observa-
tions [33]. Thus, taken together, these data indicate that
Fig. 1. Susceptibility of HT-29 cells to TNF. HT-29 cells were treated with TNF at the dose indicated for di¡erent time periods. Cells were
then examined for viability by the MTT assay. Results are the meanUS.D. of ¢ve independent experiments. P6 0.05 vs. control (A). Parallel
samples of HT-29 cells after TNF (280 ng/ml) exposure were stained with DNA-binding £uorochrome H33258 to assess chromatin integrity by
£uorescence microscopy, examining at least 5^10 random ¢elds per condition. Representative images of control and TNF-exposed HT-29 cells
are shown (B).
Table 1
GSLs generation in HT-29 cells and HT-29 clones stably transfected with antisense GD3 synthase
TNF NB-DNJ+TNF As-GD3 As-GD3+TNF
LactCer 187U 24* 37U 12** 83U 14 151U 14#
GM3 258U 31* 42U 17** 148U 21* 231U 18#
GM1 162U 21* 67U 14** 95U 12 147U 17#
GD3 267U 37* 81U 13** 32U 8* 57U 12*
HT-29 cells and clones expressing antisense GD3 synthase (As-GD3) were incubated with TNF (280 ng/ml) for 12 h and the pattern of GSLs
was quantitated by densitometric analyses of HPTLC plates. Results are expressed as percentage of values seen in control HT-29 cells in the
absence of TNF exposure (meanUS.D., four independent determinations) (0.7U 0.04; 0.3 U 0.02; 1.8 U 0.2; 2.2U 0.3 nmol/mg protein, for
LactCer, GM3, GM1 and GD3, respectively). *P6 0.05 vs. control; **P6 0.05 vs. TNF alone; P6 0.05 vs. As-GD3.
FEBS 26383 14-8-02 Cyaan Magenta Geel Zwart
A. Colell et al./FEBS Letters 526 (2002) 135^141 137
ASMase contributes to TNF-mediated apoptosis in HT-29
cells and that this e¡ect is not due to the downregulation of
ceramide levels. Since TNF generates distinct ceramide pools
through activation of NSMase as well as ASMase, these data
argue for a speci¢c role of ceramide generated by ASMase in
the TNF-mediated apoptosis.
3.2. Inhibition of GluCer synthase prevents the susceptibility of
HT-29 cells to TNF
The preceding data indicate that ASMase is required for
e⁄cient TNF-K-mediated apoptosis in HT-29 cells. Since
ASMase generates ceramide which, in turn, fuels GSLs for-
mation, we next estimated the contribution of GSLs in this
event. To address this issue, the generation of GSLs by TNF-
K was determined with or without inhibition of GluCer syn-
thase, a Golgi resident enzyme that forms GluCer, the pre-
cursor of the family of GSLs. GSLs formation, including the
globoseries GSLs GluCer and LactCer, as well as gangliosides
GM1, GM3 and GD3, was analyzed by HPTLC (Fig. 3A).
TNF stimulated the levels of LactCer, GM1, GM3 and GD3
above control values (Table 1). NB-DNJ, a speci¢c inhibitor
of GluCer synthase, decreased the basal levels of GSLs
(Fig. 3A), in agreement with previous in vivo ¢ndings [38].
Of greater relevance was the fact that NB-DNJ pretreatment
prevented the TNF-stimulated generation of these GSLs (Ta-
ble 1). The ability of NB-DNJ to downregulate GSLs, and to
block the TNF enhancement of various GSLs is consistent
with its mode of action inhibiting the ¢rst step in the stepwise
addition of monosaccharides on to ceramide [38]. Indeed, in
line with these observations, Bassi et al. have recently shown
Fig. 2. Involvement of ASMase in TNF-mediated cell death. HT-29
cells were treated with TNF (280 ng/ml) for 12 h in the absence or
presence of imipramine (20 WM). Cell extracts were isolated and re-
solved by SDS^PAGE followed by incubation with antiserum anti-
ASMase (A). Parallel cell extract aliquots were used for ASMase
(B) or NSMase (C) activity determined from [N-methyl-
14C]sphingomyelin (56.6 mCi/mmol) hydrolysis. Cells were then
treated with chloroform:methanol and lipid extracts used for ceram-
ide determination by HPLC (D). Survival of HT-29 cells after TNF
(280 ng/ml) for 20 h with or without imipramine treatment was de-
termined by MTT assay (E). Results are the meanUS.D. of ¢ve in-
dependent experiments. *P6 0.05 vs. control; **P6 0.05 vs. TNF.
Fig. 3. Pattern of GSLs generation in response to TNF. A: Control
HT-29 cells or HT-29 clones transfected with antisense GD3 syn-
thase expression vectors (As-GD3) were treated with TNF (280 ng/
ml) for 12 h in the absence or presence of NB-DNJ (30 WM). Cellu-
lar extracts were treated with chloroform:methanol for total lipid
isolation and GSLs were resolved and identi¢ed by comparison with
authentic standards as shown. B: HT-29 cells were treated with
TNF (280 ng/ml) for 20 h in the presence or absence of NB-DNJ
and cell survival determined by MTT assay. Results are the
meanUS.D. of ¢ve independent experiments. *P6 0.05 vs. control;
**P6 0.05 vs. TNF.
Fig. 4. Susceptibility of HT-29 cells expressing antisense GD3 syn-
thase to TNF. HT-29 cells were transfected with mammalian expres-
sion vector pCR3.1 containing the antisense GD3 synthase cDNA
(As-GD3) or empty vector alone (control). Selection of positive
clones was determined by geneticin-resistant cells and insert veri¢ca-
tion was determined by PCR as described in Section 2. Control and
As-GD3 cells were then treated with TNF in the absence (A) or
presence of actinomycin D (2 ng/ml) (B) for 20 h and cell survival
was determined by MTT assay. Please note the di¡erence in scale of
TNF in panels A and B. Results are the meanUS.D. of ¢ve inde-
pendent experiments. *P6 0.05 vs. control.
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that preincubation of C6 glioma cells with NB-DNJ dimin-
ishes the levels of ganglioside GM3 [39]. In order to address
the question of whether GSLs are instrumental for e⁄cient
TNF-mediated apoptosis, we assessed the e¡ect of NB-DNJ
preincubation on the susceptibility of HT-29 cells to TNF-
induced cytotoxicity. As shown, NB-DNJ protected HT-29
cells against TNF exposure (Fig. 3B). Since TNF enhanced
the levels of various GSLs this outcome obtained upon block-
ing GluCer synthase clearly indicates the involvement of
GSLs in TNF-mediated apoptosis. However, this approach
does not allow us to incriminate a speci¢c GSLs species as
a key intermediate contributing to TNF-induced apoptosis in
HT-29 cells.
3.3. Depletion of GD3 synthase prevents TNF-mediated
cell death
Because of the limitation in the interpretation of the pre-
ceding ¢ndings and due to the putative role of GD3 as an
emerging apoptotic lipid e¡ector, we examined the speci¢c
role of GD3 in TNF-mediated apoptosis in HT-29 cells. To
accomplish this aim we focused on GD3 synthase, the enzyme
responsible for the synthesis of GD3 from its precursor GM3.
GD3 synthase was downregulated by transfection with anti-
sense expression vectors before exposure to TNF. As expected
there was a signi¢cant downregulation of GD3 synthase ac-
tivity by 45U 7% (P6 0.05), an approach that resulted in the
depletion of GD3 levels in HT-29 clones expressing the anti-
sense GD3 synthase (Table 1). This e¡ect on GD3 was ac-
companied by enhanced GM3 levels (Table 1), consistent with
the formation of GD3 from GM3 upon the addition of a
second sialic acid residue. Indeed, these ¢ndings with HT-29
cells are in agreement with previous ¢ndings in F-11 cells
transfected with antisense GD3 synthase [37]. Of broader sig-
ni¢cance was the fact that under these circumstances TNF
failed to enhance the levels of GD3 in cells transfected with
antisense GD3 synthase, yet, as expected TNF did increase
the levels of LactCer and gangliosides GM1 and GM3 (Table
1). Finally, we next examined the susceptibility of the clones
expressing the antisense GD3 synthase towards TNF-induced
apoptosis. Compared with controls HT-29 cells transfected
with vector alone, HT-29 clones expressing antisense GD3
synthase displayed a marked resistance to TNF-mediated ap-
Fig. 5. Cellular distribution of GD3 by TNF. A: HT-29 cells were immunostained with antibodies anti-GD3 and anti-mitochondrial, followed
by appropriate secondary antibodies. Merged images of red (GD3) and green (mitochondria) £uorescence were collected in a confocal micro-
scope. B: HT-29 cells were treated with TNF (280 ng/ml), for 8 h and then cells were ¢xed and immunostained for GD3 and mitochondria lo-
calization. At least 100 cells per condition were examined. Less than 10% of control cells displayed merged £uorescence, while those exhibiting
co-localization by TNF were observed in more than 85% of the cells examined. Representative images of four independent experiments showing
similar results. Bar is 10 Wm.
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optosis (Fig. 4A). Furthermore, the loss of susceptibility to-
wards TNF was seen after initial sensitization by actinomycin
D as well (Fig. 4B), further supporting the protection of GD3
synthase downregulation against TNF-induced cytotoxicity.
Although these data pinpoint the speci¢c role of GD3 deple-
tion in apoptosis signaling by TNF, the putative role of other
enzymes involved in the metabolism of GM3 remains to be
addressed. These ¢ndings, however, suggest a role for GD3 as
a putative apoptotic e¡ector contributing to TNF-induced ap-
optosis. Indeed, our ¢ndings are in line with previous studies
reporting that the downregulation of GD3 synthase protects
di¡erent cell types against apoptotic stimuli such as Fas or
L-amyloid [31,40].
3.4. Redistribution and mitochondrial co-localization of GD3
induced by TNF
Previous studies have shown that GD3 activates the mito-
chondrial-dependent apoptosome through sequential mito-
chondrial permeability transition, cytochrome c release and
caspase activation [26^31]. While most of the support for
this novel function of GD3 has derived from in vitro studies
with isolated mitochondria, recent data showed that GD3
undergoes an intracellular redistribution to intracellular com-
partments in CEM cells after Fas exposure [32]. Indeed, the
physical interaction of GD3 with mitochondria has been re-
cently shown in CEM cells following ceramide incubation
[29]. Accordingly, we next examined whether GD3 co-local-
ized with mitochondria in response to TNF. HT-29 cells were
immunostained with primary antibodies anti-GD3 and anti-
mitochondria and observed by laser confocal microscopy. In
control, HT-29 cells, most of GD3 was localized in the plasma
membrane without evidence of co-localization of GD3 with
mitochondria (Fig. 5A). However, in response to TNF, GD3
underwent a redistribution from the cell surface to intracellu-
lar compartments including mitochondria, as revealed by the
merged £uorescence (Fig. 5B). The present ¢ndings in HT-29
cells are similar to our recent results with cultured rat hepa-
tocytes [41], and indicate that the interaction of GD3 with
mitochondria is not a cell speci¢c event. These studies in he-
patocytes have partially characterized the tra⁄cking of gan-
glioside GD3 to mitochondria through actin cytoskeleton ve-
sicular movement sensitive to actin-disrupting agents [41].
Indeed, we observed that pretreatment of HT-29 cells with
latrunculin A, an actin-disrupting agent which depolymerized
actin ¢laments, protected HT-29 cells against TNF-mediated
cell death (not shown). Together, these ¢ndings highlight the
relevance of the tra⁄cking of GD3 to mitochondria in TNF
apoptosis signaling and imply that the regulation of the traf-
¢cking of endosomal vesicles loaded with GD3 to mitochon-
dria emerges as a novel strategy in the modulation of apopto-
sis.
Thus, the present study adds further support for a role of
GD3 in TNF-mediated apoptosis since its speci¢c depletion
through downregulation of GD3 synthase protects HT-29
cells against TNF-induced cell death. Our work documents
for the ¢rst time the functional relation between ASMase
activation and GD3 generation in TNF-induced apoptosis in
human colon epithelial cells. The regulation of GD3 genera-
tion and/or its intracellular tra⁄cking may prove useful in the
modulation of cell death by death ligands. However, further
work will be required to further characterize the intracellular
movement of GD3 as well as the transcriptional regulation of
GD3 synthase, which may be of relevance in the modulation
of apoptosis induced by death ligands.
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